The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Bristol Myers Squibb today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi ® in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary ...

BREYANZI can increase the risk of life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

Key Takeaways Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a ...

Breyanzi can cause serious life-threatening side effects, such as cytokine release syndrome, neurologic toxicities and secondary malignancies. Please see the important safety information further ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Breyanzi is also indicated for the treatment of large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.

Bristol Myers Squibb today announced the U.S. Food and Drug Administration has granted accelerated approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the ...

Breyanzi carries a Boxed Warning regarding the risk for cytokine release syndrome and neurologic toxicities including fatal or life-threatening reactions. It is available only through a restricted ...